RECENT NEWS

Healthcare industry innovator Dr Melanie Ivarsson has been appointed as CEO of the HDRS to accelerate medical breakthroughs.

The MHRA is setting out the next phase of clinical trial reforms for 2026, aimed at helping patients access new cutting-edge treatments more quickly and boosting the UK’s competitiveness for global clinical research.

A new technique which slashes the time taken to diagnose microbial infections from days to minutes could help save lives and open up a new front in the battle against antibiotic resistance, researchers say.

AI-powered pathology firm PathAI has announced a strategic collaboration with University Hospital Zurich (USZ) to deploy digital pathology platform AISight Dx, together with AIM-TumorCellularity (AIM-TC) to support tumour cell content (TCC) quantification in routine molecular workflows.

Researchers at WashU Medicine and their collaborators have created an immune cell atlas of multiple myeloma, a cancer of the bone marrow. The new resource could improve prognosis and guide development of new immunotherapies.

More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.

Noul Co, a company specialising in AI-powered blood and cancer diagnostics, recently showcased its AI-based cervical cancer diagnostic solution, miLab CER at the technology event CES 2026.

Medical Wire & Equipment (MWE) has announced that the Fecal Transwab with Liquid Cary Blair Medium Specimen Collection and Transport System has received FDA 510(k) clearance for the preservation and transport of faecal specimens for microbiological testing in clinical laboratories.

Precision medicine firm Sophia Genetics and The University of Texas MD Anderson Cancer Center have announced a strategic collaboration that unites Sophia’s AI-powered analytics with MD Anderson's clinical and scientific expertise.

US diagnostic firm CorePlus has announced the implementation of AIxURO, a state-of-the-art software solution that utilises artificial intelligence to significantly improve the accuracy and efficiency of bladder cancer detection.

A groundbreaking international study has shown that Alzheimer's disease biomarkers can be accurately detected using simple finger-prick blood samples.

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

FUJIFILM Healthcare UK has announced the signing of a Memorandum of Understanding (MOU) with Llusern Scientific, a Cardiff-based specialist in rapid point-of-care molecular diagnostics designed specifically to detect bacterial and viral infections.

Two newly published studies from Cleveland Clinic researchers have found that elevated bacteria levels in head and neck cancer tumours weaken the immune response, paving the way for new therapeutic strategies.

Consultant histopathologist and medical examiner Suzy Lishman has been made a Dame in the King's New Year's Honours, for her work on the implementation of the national medical examiner service.

A new £2 million pilot scheme will see health visitors reach families facing barriers to vaccines, to ensure more children are protected.

Five new studies funded by the Medical Research Council (MRC) will investigate neurodegenerative diseases that give rise to dementia.

AI cancer diagnostics and precision oncology firm Lunit has announced that a new study evaluating its AI-powered pathology solution, Lunit SCOPE HER2, has been published, in which it demonstrates high concordance with pathologists in HER2 interpretation for advanced biliary tract cancer (cholangiocarcinoma).

US diagnostics firm Next Gen Diagnostics (NGD) has announced that it will spin off its Infection Prevention division into an independent company, NGD Infection Prevention, focused on the implementation of real-time genomic transmission detection across American hospitals.

Understanding gut microbiome interactions with medicines could help explain differences in how people respond to treatment and build on existing medicine safety knowledge to support safer, more effective prescribing in the future, according to a new review.